CSPC INNOVATION PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.01 CNY | -0.76% |
|
+0.86% | +11.45% |
| Apr. 22 | CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 19 | China's drugmakers can't sell mRNA shots but haven't quit yet | RE |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8,376 | 9,767 | 42,873 | 47,770 | - | - |
| Enterprise Value (EV) 1 | 8,376 | 9,767 | 39,451 | 46,202 | 42,771 | 41,154 |
| P/E ratio | 26.4 x | 13.4 x | 56.1 x | 59.4 x | 46.6 x | 37.3 x |
| Yield | - | 0.95% | 0.87% | 0.78% | 0.38% | 0.63% |
| Capitalization / Revenue | - | 3.72 x | 17.1 x | 15.5 x | 11.8 x | 8.42 x |
| EV / Revenue | - | 3.72 x | 15.8 x | 15 x | 10.6 x | 7.26 x |
| EV / EBITDA | - | 10.5 x | 45.5 x | 51.1 x | 33.2 x | 22.9 x |
| EV / FCF | - | - | 47.2 x | 193 x | 46 x | 26.6 x |
| FCF Yield | - | - | 2.12% | 0.52% | 2.18% | 3.76% |
| Price to Book | - | 2.48 x | 8.44 x | 8.72 x | 6.43 x | 5.38 x |
| Nbr of stocks (in thousands) | 1,179,360 | 1,336,881 | 1,404,891 | 1,404,593 | - | - |
| Reference price 2 | 7.102 | 7.306 | 30.52 | 34.01 | 34.01 | 34.01 |
| Announcement Date | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 2,626 | 2,502 | 3,089 | 4,049 | 5,672 |
| EBITDA 1 | - | 927.7 | 867 | 904.8 | 1,289 | 1,800 |
| EBIT 1 | - | 855.6 | 891.3 | 1,016 | 1,205 | 1,538 |
| Operating Margin | - | 32.58% | 35.63% | 32.87% | 29.76% | 27.12% |
| Earnings before Tax (EBT) 1 | - | 851.4 | 891.8 | 890.6 | 1,286 | 1,812 |
| Net income 1 | 317.1 | 726.3 | 755.6 | 805.8 | 1,060 | 1,403 |
| Net margin | - | 27.65% | 30.2% | 26.08% | 26.18% | 24.73% |
| EPS 2 | 0.2685 | 0.5432 | 0.5444 | 0.5721 | 0.7305 | 0.9129 |
| Free Cash Flow 1 | - | - | 835.3 | 239.7 | 930.5 | 1,548 |
| FCF margin | - | - | 33.39% | 7.76% | 22.98% | 27.3% |
| FCF Conversion (EBITDA) | - | - | 96.33% | 26.49% | 72.16% | 86.03% |
| FCF Conversion (Net income) | - | - | 110.55% | 29.74% | 87.78% | 110.39% |
| Dividend per Share 2 | - | 0.0694 | 0.2667 | 0.2667 | 0.1295 | 0.2151 |
| Announcement Date | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 3,421 | 1,569 | 4,999 | 6,616 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 835 | 240 | 930 | 1,548 |
| ROE (net income / shareholders' equity) | - | 20.1% | 16.2% | 14.9% | 15.1% | 15.5% |
| ROA (Net income/ Total Assets) | - | - | 14.8% | 11.7% | 13.7% | 14.9% |
| Assets 1 | - | - | 5,108 | 6,859 | 7,757 | 9,446 |
| Book Value Per Share 2 | - | 2.940 | 3.620 | 3.900 | 5.290 | 6.320 |
| Cash Flow per Share 2 | - | 0.4800 | 0.6600 | 0.5200 | 0.7000 | 0.9600 |
| Capex 1 | - | 108 | 92 | 184 | 133 | 179 |
| Capex / Sales | - | 4.12% | 3.68% | 5.96% | 3.28% | 3.15% |
| Announcement Date | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.01
CNY
Average target price
40.1
CNY
Spread / Average Target
+17.90%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.45% | 6.65B | |
| +16.16% | 8.15B | |
| +3.59% | 7.52B | |
| -7.15% | 3.73B | |
| -6.11% | 3.72B | |
| +1.10% | 1.31B | |
| +15.20% | 972M | |
| -36.30% | 958M | |
| -16.77% | 876M | |
| -18.44% | 783M |
- Stock Market
- Equities
- 300765 Stock
- Financials CSPC Innovation Pharmaceutical Co., Ltd.